Inarigivir soproxil

CAS: 942123-43-5 F: C25H34N7O13PS W: 703.62

Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable prodrug of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV[1][2].
Target	EC50: 2.2/1.0 μM (HCV 1a/1b).
Invitro	Inarigivir soproxil (SB 9200) is a first-in-class oral modulator of innate immunity that acts via the activation of the RIG-I and NOD2 pathways[1]. Inarigivir soproxil is an effective inhibitor of HCV replication in cell culture. The antiviral activity of Inarigivir soproxil against HCV was assessed using genotype 1 HCV replicon systems in duplicate experiments using 4 drug concentrations. Inarigivir soproxil inhibits HCV replication with EC50s of 2.2 and 1.0 µM, and EC90s of 8.0 and 6.0 µM for genotype 1A and 1B, respectively[1].Inarigivir soproxil (SB 9200), an orally bioavailable dinucleotide, activates the viral sensor proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) causing the induction of the interferon (IFN) signaling cascade for antiviral defense[2].
In Vivo	The induction of host immune responses by pretreatment with Inarigivir soproxil (SB 9200) followed by Entecavir (ETV) resulted in antiviral efficacy that was superior to that obtained using the strategy of viral reduction with ETV followed by immunomodulation[2].Sequential treatment of chronic WHV carrier woodchucks with Inarigivir soproxil (30 mg/kg)followed by ETV induced marked suppression of serum viremia and antigenemia and delayed recrudescence of viral replication compared to sequential treatment with ETV followed by Inarigivir soproxil[2]. Animal Model:
Name	Inarigivir soproxil
CAS	942123-43-5
Formula	C25H34N7O13PS
Molar Mass	703.62
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	-20°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Reference	[1]. Meleri Jones, et al. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89(9):1620-1628. [2]. Manasa Suresh, et al. Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One. 2017 Jan 5;12(1):e0169631.